Zurück
weitere 400k $
ROCHESTER, N.Y., Jul 12, 2006 (BUSINESS WIRE) --
Biophan Technologies, Inc. (OTCBB: BIPH) (FWB: BTN), a developer of next-generation medical technology, announced today that the Full Senate Appropriations Committee has approved $400,000 in the Fiscal Year 2007 Energy and Water Appropriations Bill for research on the MYO-VAD cardiac assist device at the Rochester Heart Institute at Rochester General Hospital.
With the aid of this funding, Rochester Heart Institute and MYOTECH will develop a new generation of minimally invasive cardiac assist devices for patients both in urban and rural communities. Existing cardiac assist devices are available only at specialized cardiac and transplant centers. The technically simple MYO-VAD promises to be available at virtually every hospital. MYOTECH is also working with the Greater Rochester Enterprise to establish clinical research and device manufacturing capacity in Monroe County, New York.
The MYO-VAD employs a technology which has already saved human lives. It is the only device that can both restore a fully arrested heart and maintain full cardiac output from a weak or damaged heart. The device can be installed in a 3-4 minute procedure, compared to current ventricular assist devices (VAD\'s) that take 30-45 minutes. Additionally, the MYO-VAD does not contact circulating blood, avoiding the complications of clotting and stroke, bleeding, and infection that plague current VAD\'s. The early prototypes using this technology restored full cardiac output in patients who were dying, and are alive and well today.
"We are very pleased to have the Senate Appropriations committee recognize the importance and value of our efforts with Rochester Heart Institute. We are also grateful to Senator Hillary Rodham Clinton who secured the funding for Rochester Heart Institute. Biophan remains committed to bring the MYO-VAD to market. The clinical need for this device is overwhelming. This money is incremental to the previous $1 million which was announced last week by the House of Representatives, and brings to $1.4 million the combined allocation for the MYO-VAD project," stated Michael Weiner, Biophan CEO.
Additional information on the MYO-VAD can be found on the Biophan website at www.biophan.com/myo-vad/index.php. Physicians and healthcare professionals may wish to view the Video Series at www.biophan.com/myo-vad/myo-vadAllVideos.php.
ROCHESTER, N.Y., Jul 12, 2006 (BUSINESS WIRE) --
Biophan Technologies, Inc. (OTCBB: BIPH) (FWB: BTN), a developer of next-generation medical technology, announced today that the Full Senate Appropriations Committee has approved $400,000 in the Fiscal Year 2007 Energy and Water Appropriations Bill for research on the MYO-VAD cardiac assist device at the Rochester Heart Institute at Rochester General Hospital.
With the aid of this funding, Rochester Heart Institute and MYOTECH will develop a new generation of minimally invasive cardiac assist devices for patients both in urban and rural communities. Existing cardiac assist devices are available only at specialized cardiac and transplant centers. The technically simple MYO-VAD promises to be available at virtually every hospital. MYOTECH is also working with the Greater Rochester Enterprise to establish clinical research and device manufacturing capacity in Monroe County, New York.
The MYO-VAD employs a technology which has already saved human lives. It is the only device that can both restore a fully arrested heart and maintain full cardiac output from a weak or damaged heart. The device can be installed in a 3-4 minute procedure, compared to current ventricular assist devices (VAD\'s) that take 30-45 minutes. Additionally, the MYO-VAD does not contact circulating blood, avoiding the complications of clotting and stroke, bleeding, and infection that plague current VAD\'s. The early prototypes using this technology restored full cardiac output in patients who were dying, and are alive and well today.
"We are very pleased to have the Senate Appropriations committee recognize the importance and value of our efforts with Rochester Heart Institute. We are also grateful to Senator Hillary Rodham Clinton who secured the funding for Rochester Heart Institute. Biophan remains committed to bring the MYO-VAD to market. The clinical need for this device is overwhelming. This money is incremental to the previous $1 million which was announced last week by the House of Representatives, and brings to $1.4 million the combined allocation for the MYO-VAD project," stated Michael Weiner, Biophan CEO.
Additional information on the MYO-VAD can be found on the Biophan website at www.biophan.com/myo-vad/index.php. Physicians and healthcare professionals may wish to view the Video Series at www.biophan.com/myo-vad/myo-vadAllVideos.php.
